Target type: molecularfunction
Binding to a P-TEFb complex. [GOC:pga, PMID:18391197]
P-TEFb, a critical regulator of transcription elongation, exerts its influence by binding to and phosphorylating the C-terminal domain (CTD) of RNA polymerase II (RNAPII). This interaction is crucial for facilitating the transition from transcription initiation to elongation. The P-TEFb complex comprises two subunits: cyclin-dependent kinase 9 (CDK9) and cyclin T1 or cyclin T2. CDK9, a serine/threonine kinase, possesses the catalytic activity responsible for phosphorylating the CTD. The CTD of RNAPII is a highly conserved, repetitive sequence consisting of heptapeptide repeats with the consensus sequence YSPTSPS. P-TEFb specifically targets Serine 2 (Ser2) within these repeats, leading to its phosphorylation. Phosphorylation of Ser2 on the CTD serves as a molecular switch, triggering a cascade of events that promote elongation. Notably, the recruitment of P-TEFb to the transcription machinery is tightly regulated. It is believed that P-TEFb exists in an inactive state within the cell, bound to the 7SK snRNP complex. Upon receiving signals, such as the presence of paused RNAPII or the activation of signaling pathways, P-TEFb is released from the 7SK snRNP complex and becomes available for recruitment to the transcription site. The precise mechanism of P-TEFb recruitment varies depending on the specific gene and regulatory context. Once recruited to the transcription site, P-TEFb phosphorylates Ser2 on the CTD of RNAPII, facilitating the transition from initiation to elongation. This phosphorylation event triggers several downstream effects, including: (1) recruitment of elongation factors, such as SII and TFIIS, which enhance the processivity of RNAPII; (2) dissociation of negative elongation factors (NELFs), which hinder elongation; (3) recruitment of splicing factors, facilitating the removal of introns from the nascent RNA transcript; (4) recruitment of polyadenylation factors, initiating the process of mRNA 3'-end processing. In summary, P-TEFb binding and its associated Ser2 phosphorylation of the CTD play a pivotal role in regulating transcription elongation, ensuring efficient and accurate production of mRNA molecules.'
"
Protein | Definition | Taxonomy |
---|---|---|
Bromodomain-containing protein 4 | A bromodomain-containing protein 4 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O60885] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
alprazolam | alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug. Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238) | organochlorine compound; triazolobenzodiazepine | anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic |
ly 303511 | LY 303511: inhibitor of phosphatidylinositol 3-kinase | N-arylpiperazine | |
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source | chromones; morpholines; organochlorine compound | autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector |
entinostat | benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline | antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor | |
sb 202190 | 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase | imidazoles; organofluorine compound; phenols; pyridines | apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor |
vorinostat | vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL). Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME. | dicarboxylic acid diamide; hydroxamic acid | antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor |
ferrocin c | N-methyl-2-quinolone: structure in first source | ||
n-methylpyrrolidone | 1-methylpyrrolidin-2-one: structure in first source N-methylpyrrolidin-2-one : A member of the class of pyrrolidine-2-ones that is pyrrolidin-2-one in which the hydrogen attached to the nitrogen is replaced by a methyl group. | lactam; N-alkylpyrrolidine; pyrrolidin-2-ones | polar aprotic solvent |
4-Methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one | benzodiazepine | ||
nitroxoline | nitroxoline : A monohydroxyquinoline in which the hydroxy group is positioned at C-8 with a nitro group trans to it at C-5. nitroxoline: structure in Merck Index, 9th ed, #6475; RN given refers to parent cpd | C-nitro compound; monohydroxyquinoline | antifungal agent; antiinfective agent; antimicrobial agent; renal agent |
n-hydroxysuccinimide | N-hydroxysuccinimide: structure | ||
lenalidomide | aromatic amine; dicarboximide; isoindoles; piperidones | angiogenesis inhibitor; antineoplastic agent; immunomodulator | |
2-methyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-4-one | organonitrogen heterocyclic compound; oxacycle | ||
methyl indole-3-carboxylate | methyl indole-3-carboxylate : The methyl ester of indole-3-carboxylic acid. | indoles; methyl ester | metabolite |
2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-1-benzopyran-4-one | flavones | ||
romidepsin | depsipeptide : A natural or synthetic compound having a sequence of amino and hydroxy carboxylic acid residues (usually alpha-amino and alpha-hydroxy acids), commonly but not necessarily regularly alternating. | cyclodepsipeptide; heterocyclic antibiotic; organic disulfide | antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor |
belinostat | hydroxamic acid; olefinic compound; sulfonamide | antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor | |
panobinostat | panobinostat : A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma. Panobinostat: An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA. | cinnamamides; hydroxamic acid; methylindole; secondary amino compound | angiogenesis modulating agent; antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor |
6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- | organonitrogen heterocyclic compound; organosulfur heterocyclic compound | ||
volasertib | BI 6727: a polo-like kinase inhibitor with broad antitumor activity; structure in first source | ||
nu 7441 | 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one: structure in first source | dibenzothiophenes | |
bi 2536 | |||
N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide | sulfonamide | ||
tg101209 | N-alkylpiperazine; N-arylpiperazine; pyrimidines; secondary amino compound; sulfonamide | antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | |
fedratinib | fedratinib: a selective small-molecule inhibitor of JAK2 | sulfonamide | |
ro3280 | RO3280: inhibits polo-like kinase 1; structure in first source | ||
bi d1870 | |||
xmd 8-92 | XMD8-92 : A dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one carrying at C-2 on the pyrimidine ring a [2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenyl]amino substituent. It is an inhibitor of the BMK1 kinase pathway. | pyrimidobenzodiazepine | protein kinase inhibitor |
lrrk2-in1 | LRRK2-IN1: inhibits leucine-rich repeat kinase 2; structure in first source | aromatic amine; aromatic ether; N-acylpiperidine; N-alkylpiperazine; pyrimidobenzodiazepine; secondary amino compound; tertiary amino compound | antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor |
jq1 compound | carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine | angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer | |
dinaciclib | pyrazolopyrimidine | ||
gsk525762a | molibresib: mimicks acetylated histones; structure in first source | benzodiazepine | |
LSM-6732 | organonitrogen heterocyclic compound; organosulfur heterocyclic compound; tert-butyl ester | ||
gsk1210151a | GSK1210151A: inhibitor of the BET family of proteins; structure in first source | imidazoquinoline | |
i-bet726 | |||
pelabresib | CPI-0610: a bromodomain and extra-terminal protein inhibitor with antineoplastic activity; structure in first source | monochlorobenzenes; organic heterotricyclic compound; primary carboxamide | antineoplastic agent; bromodomain-containing protein 4 inhibitor |
MS-417 | MS-417 : A member of the class of thienotriazolodiazepines that is the methyl ester of [(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetic acid. A bromodomain and extra-terminal domain (BET)-specific inhibitor that belongs to a group of thienodiazepine-based compounds | methyl ester; monochlorobenzenes; thienotriazolodiazepine | |
sf 1126 | SF 1126: an LY294002 prodrug and pan PI3K inhibitor; structure in first source | ||
2-methoxy-n-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide | 2-methoxy-N-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide: a probe for bromo and extra C-terminal domain proteins; structure in first source | quinazolines | |
cpi203 | CPI203: a BET protein bromodomain inhibitor | ||
pf-06687252 | PF-06687252: a SMARCA2/4 bromodomain inhibitor; structure in first source PFI-3 : An azabicycloalkane that is (1R,4R)-2,5-diazabicyclo[2.2.1]heptane which is substituted at position 2 by a 3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl group and at position 5 by a pyridin-2-yl group. It is a potent and selective inhibitor of polybromo 1 (Kd = 48 nM), SMARCA2 and SMARCA4 (Kd = 89 nM) bromodomains. | azabicycloalkane; enone; phenols; pyridines | |
dBET6 | organic molecular entity | ||
MZ1 | organic molecular entity | ||
rvx 208 | apabetalone: a bromodomain and extra-terminal domain protein (BET) inhibitor; prevents interactions between BET proteins and acetyl-lysine residues on histone tails to modify epigenetic regulation | ||
pp242 | torkinib : A member of the class of pyrazolopyrimidines that is 1H-pyrazolo[3,4-d]pyrimidine substituted by isopropyl, 5-hydroxyindol-2-yl and amino groups at positions 1, 3 and 4 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties. | aromatic amine; biaryl; hydroxyindoles; phenols; primary amino compound; pyrazolopyrimidine | antineoplastic agent; mTOR inhibitor |